Advertisement

Topics

Tibotec Therapeutics Company Profile

01:14 EST 21st January 2017 | BioPortfolio


News Articles [1860 Associated News Articles listed on BioPortfolio]

PX'Therapeutics und RELIEF THERAPEUTICS Holding AG kündigen strategischen Kooperationsvertrag für rekombinante Produktion von Atexakin Alfa an

PX'Therapeutics, Tochtergesellschaft des Aguettant Konzerns, ein Unternehmen, das sich auf die kundenspezifische Entwicklung rekombinanter Proteine konzentriert, und die RELIEF THERAPEUTICS Holdin...

Research Reports Initiation on Biotech Stocks -- Regulus Therapeutics, Abeona Therapeutics, ...

Regulus Therapeutics  San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...

Domain Therapeutics sets up Mavalon Therapeutics, with financial backing from Medicxi

French drug discovery company Domain Therapeutics today announced the creation of Mavalon Therapeutics,…

Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, ...

http://stock-callers.com/registration Celldex Therapeutics  On Thursday, shares in Hampton, New Jerseyheadquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, whi...

Relief Therapeutics kündigt strategische Allianz mit PX'Therapeutics an

Genf/Grenoble (awp) - Das Biotechunternehmen Relief Therapeutics kündigt eine strategische Zusammenarbeit mit PX'Therapeutics an. Gemeinsam werden die beiden Unternehmen an der Produktion von Atexa.....

Antegrin and Cascadia merge to form Indalo Therapeutics

Antegrin Therapeutics and Cascadia Therapeutics have established Indalo Therapeutics, a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases.

Bicycle Therapeutics signs cancer development deal with CRUK

Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of thera...

Magenta Therapeutics Announces $48.5M Financing

NewsMagenta Therapeutics aspires to develop a patient-focused set of therapeutics with the first complete platform that addresses the critical challenges in stem cell transplant.

Drugs and Medications [0 Results]

None

Clinical Trials [22 Associated Clinical Trials listed on BioPortfolio]

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

This is an open-label safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV)...

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

The primary objective is to continue the provision of etravirine (ETR) for patients who previously received ETR in a clinical pediatric trial sponsored by or in collaboration with Tibotec,...

Companies [16 Associated Companies listed on BioPortfolio]

Tibotec, Inc

Tibotec is a pharmaceutical research and development company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. T...

Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Y...

Tibotec Inc.

Tibotec Inc., based in Yardley, Pa., USA, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Cork, Ir...

Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with off...

Antegrin Therapeutics, Inc.

Antegrin Therapeutics, Inc., is a pharmaceutical company dedicated to developing novel treatments for fibrotic diseases. The company aims to select its first clinical development ...

More Information about "Tibotec Therapeutics" on BioPortfolio

We have published hundreds of Tibotec Therapeutics news stories on BioPortfolio along with dozens of Tibotec Therapeutics Clinical Trials and PubMed Articles about Tibotec Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tibotec Therapeutics Companies in our database. You can also find out about relevant Tibotec Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record